Hormone receptor-positive early breast cancer: Controversies in the use of adjuvant chemotherapy

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1091-1102

  Montemurro, Filippo ^a   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE;

ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGNOSIS; REVIEW; STOMATITIS; SURVIVAL TIME; VOMITING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 72549105742     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0033     Document Type: Review

References (58)

1. Albain K, Barlow O & O'Malley F 2004 Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase II intergroup trial 0100 (SWOG-8814). Breast Cancer Research and Treatment 88 (Supplement 1) S20 (abstract 37).
2. th Annual San Antonio Breast Cancer Symposium, General Session 1, abstract LBA10, available http://www.abstracts2view.com/sabcs07/view.php?nu=SABCS07L-1165.
3. Allred DC, Harvey JM, Berardo M & Clark GM 1998 Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology 11 155-168. (Pubitemid 28144151)
4. Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, Hortobagyi GN & Pusztai L 2008 Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. Journal of Clinical Oncology 26 2636-2643.
5. ATAC Trialists 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncology 9 45-53.
6. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L et al. 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. Journal of the American Medical Association 295 1658-1667.
7. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M et al. 2005 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. Journal of Clinical Oncology 23 5138-5147. (Pubitemid 46224022)
8. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L et al. 1998 Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. Journal of the National Cancer Institute 90 1205-1211.
9. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN et al. 2003 Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal of Clinical Oncology 21 1431-1439. (Pubitemid 46594092)
10. Clark GM, Osborne CK & McGuire WL 1984 Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. Journal of Clinical Oncology 2 1102-1109. (Pubitemid 14022697)
11. Colleoni M, Bagnardi V, Rotmensz N, Gelber R, Viale G, Pruneri G, Veronesi P, Torrisi R, Cardillo A, Montagna E et al. 2008 Increasing steroid hormone receptor expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Research and Treatment 116 359-369.
12. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, van de Velde CJ, Delozier T, Alvarez I et al. 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 559-570. (Pubitemid 46251559)
13. Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M & Sainsbury R 2007 Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369 1711-1723.
14. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 1687-1717. (Pubitemid 40719106)
15. Eierman W, Pienkowski T, Crown J, Chap L, Pawliki M, Martin M, Saleh M, Sehdev S, Provencher L, Von Minckwitz G et al. 2009 BCIRG 005: main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cycloposphamide followed by docetaxel (AC ⇒ T) in women with HER-2/neu negative axillary lymph node positive early breast cancer. Cancer Research 69 (Supplement) (abstract 77).
16. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R et al. 2009 Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 373 1681-1692.
17. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN et al. 1997 Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. Journal of the National Cancer Institute 89 1673-1682. (Pubitemid 27508191)
18. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U & Bruzzi P 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. Journal of the National Cancer Institute 100 14-20. (Pubitemid 351767337)
19. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B & Senn HJ 2005 Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Annals of Oncology 16 1569-1583. (Pubitemid 41511089)
20. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B & Senn HJ 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Annals of Oncology 18 1133-1144. (Pubitemid 47244357)
21. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B & Senn HJ 2009 Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Annals of Oncology 20 1489-1498.
22. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE et al. 2008 Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. Journal of Clinical Oncology 26 4063-4071.
23. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI et al. 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute 97 1262-1271. (Pubitemid 41535367)
24. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN et al. 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. Journal of Clinical Oncology 24 1037-1044. (Pubitemid 46638799)
25. Habel L, Shak S, Jacobs M, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J et al. 2006 A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Research 8 R25.
26. Haibe-Kains B, Desmedt C, Sotiriou C & Bontempi G 2008 A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics 24 2200-2208.
27. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF & Bast RC Jr 2007 American Society of Clinical Oncology 2007 Update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology 25 5287-5312. (Pubitemid 350232263)
28. Hassett MJ, Hughes ME, Niland JC, Edge SB, Theriault RL, Wong YN, Wilson J, Carter WB, Blayney DW & Weeks JC 2008 Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer. Journal of Clinical Oncology 26 5553-5560.
29. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH et al. 2003 Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. Journal of Clinical Oncology 21 976-983. (Pubitemid 46594124)
30. Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M et al. 2009 Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. Journal of Clinical Oncology 27 1168-1176.
31. International Breast Cancer Study Group 2002 Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. Journal of the National Cancer Institute 94 1054-1065.
32. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F et al. 2007 Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. Journal of the National Cancer Institute 99 1845-1853. (Pubitemid 351767193)
33. Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M & Jakesz R 2006 Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncology 7 991-996. (Pubitemid 44804137)
34. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L et al. 2008 Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. Journal of Clinical Oncology 26 44-53.
35. Di Leo A & Isola J 2003 Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clinical Breast Cancer 4 179-186.
36. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A & Wolmark N 2005 Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Journal of Clinical Oncology 23 3686-3696. (Pubitemid 46252463)
37. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E et al. 2005 Adjuvant docetaxel for node-positive breast cancer. New England Journal of Medicine 352 2302-2313.
38. Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, Rodriguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacon C et al. 2006 Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Annals of Oncology 17 1205-1212. (Pubitemid 44288210)
39. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munarriz B, Rodriguez CA, Crespo C, de Alava E et al. 2008 Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute 100 805-814. (Pubitemid 351809668)
40. Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM et al. 2007 Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Annals of Oncology 18 874-880. (Pubitemid 47054084)
41. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL & Pritchard KI 2009 Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. Journal of the National Cancer Institute 101 644-650.
42. Paik S 2007 Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 12 631-635. (Pubitemid 47036199)
43. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351 2817-2826. (Pubitemid 40051905)
44. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J et al. 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology 24 3726-3734. (Pubitemid 46622311)
45. Penault-Llorca F, Andre F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC, Bibeau F, Antoine M et al. 2009 Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology 27 2809-2815.
46. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al. 2000 Molecular portraits of human breast tumours. Nature 406 747-752. (Pubitemid 30671230)
47. Peto R 2007 The World Wide Overview: new results for systemic adjuvant therapies. www.sabcs.org.
48. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH & Levine MN 2006 HER2 and responsiveness of breast cancer to adjuvant chemotherapy. New England Journal of Medicine 354 2103-2111. (Pubitemid 43736610)
49. Pusztai L 2006 Chips to bedside: incorporation of microarray data into clinical practice. Clinical Cancer Research 12 7209-7214. (Pubitemid 46095390)
50. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulie P, Eichler F et al. 2006 Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology 24 5664-5671. (Pubitemid 46631307)
51. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869-10874. (Pubitemid 32878711)
52. Sotiriou C & Pusztai L 2009 Gene-expression signatures in breast cancer. New England Journal of Medicine 360 790-800.
53. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC & Davidson NE 2008 Weekly paclitaxel in the adjuvant treatment of breast cancer. New England Journal of Medicine 358 1663-1671. (Pubitemid 351549913)
54. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M et al. 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine 353 2747-2757. (Pubitemid 43016814)
55. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW et al. 2008 Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. Journal of the National Cancer Institute 100 207-212.
56. Ward S, Simpson E, Davis S, Hind D, Rees A & Wilkinson A 2007 Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technology Assessment 11 1-144.
57. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F et al. 2008 Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Research 10 R65.
58. Younis T, Rayson D, Sellon M & Skedgel C 2008 Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Research and Treatment 111 261-267.